The Inhibitory Effect of Aspirin on Human Endothelial Cells

Summary

Human endothelial cell monolayers prepared from umbilical veins have been incubated with aspirin (1–2 mM) dissolved in Hepes modified solution and in platelet-rich plasma. They have also been incubated with plasma prepared from subjects before and after intake of aspirin giving a mean plasma concentration of 0.5 mM. The effects of the endothelial cells on ADP and collagen-induced platelet aggregation and malondialdehyde production in platelet-rich plasma have been tested. The endothelial cells had a spontaneous inhibitory effect on all three parameters. This effect was abolished when the cells were incubated with aspirin dissolved in MHS for 20 min and the increase in effect observed when platelet-rich plasma was incubated with endothelial cells for a period of 30 min was similarly inhibited when aspirin was dissolved in plasma or when plasma prepared from subjects who had taken aspirin were used. Aspirin had no inhibitory effect on prostacyclin (PGI₂) with regard to the effect of PGI₂ on platelets. On the contrary, the two compounds had an additive inhibitory effect on platelet aggregation induced by ADP and collagen. These findings should be considered with regard to the use of aspirin as an antithrombotic agent.

• References

• 1 Czervionke RL, Fry G, Hoak JC, Maca RD. 1978 Thrombin induced platelet adherence to human endothelial cells. Journal Clinical Investigation. in press
• 2 Gorman RR, Bunting S, Miller OV. 1977; Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377
• 3 Hamberg M, Svensson F, Wakabayaski T, Samuelsson B. 1974; Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proceedings of the National Academy of Sciences 71: 345
• 4 Harris WH, Salzman EW, Athanasoulis G, Waltman AG, Baum S, Desanctis RW. 1972; Comparison of Warfarin, low molecular weight dextran, aspirin and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. Journal of Bone and Joint Surgery 56: 1552
• 5 Heyns AP, Badenhorst CF, Retief FP. 1977; An aorta intima inhibitor of platelet aggregation. Thrombosis and Haemostasis (abstr.) 38: 137
• 6 Jaffe EA, Nachman RL, Becker CG, Minick CR. 1973; Culture of human endothelial cells derived from human umbilical veins. Identification by morphologic and immunologic criteria Journal of Clinical Investigations 52: 2745
• 7 Lieberman BE, Lewis GP, Peters TJ. 1977; A membrane-bound enzyme in rabbit aorta capable of inhibiting adenosine-diphosphate induced platelet aggregation. Lancet 2: 330
• 8 Medical Research Council (Report of the Steering Committee). 1972; Effect of aspirin on postoperative venous thrombosis. Lancet 2: 441
• 9 Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport ST. 1969; The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204
• 10 Minkes M, Stanford N, CHI MM-Y, Roth GJ, Raz A, Needleman P, Majerus PW. 1977; Cyclic adenosine 3’.5’-monophosphate inhibits the availability of arachidonate to prostaglandin synthesis in human platelet suspensions. Journal Clinical Investigations 59: 449
• 11 Moncada S, Higgs EA, Vane JR. 1977; Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1: 18
• 12 Moncada S, Gryzlewski RJ, Bunting S, Vane JR. 1976; A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 12: 715
• 13 Nordøy A, Svensson B, Hoak JC. 1978; The inhibitory effect of human endothelial cell monolayers on platelet reactions and its inhibition by aspirin. Thrombosis Research 12: 597
• 14 Packham MA, Nishizawa EE, Mustard JF. 1968; Response of platelets to tissue injury. Biochemistry and Pharmacology (Suppl.) 171
• 15 Roth GJ, Standford N, Majerus PW. 1975; Acetylation of prostaglandin synthase by aspirin. Proceedings of the National Academy of Sciences 72: 3073
• 16 Shen TY. 1976. Prostaglandin synthesis inhibitors. In: Berti F, Samuelsson B, Veto GP. (eds.) Prostaglandins and Thromboxanes. Plenum Press; New York: p 111-136
• 17 Smith JB, Sugerman CM, Silver JM. 1976; Malondialdehyde formation as an indicator of prostaglandin production by human platelets. Journal of Laboratory and Clinical Medicine 88: 167
• 18 Trinder P. 1957; Determination of acetylsalicylic acid. Biochemical Journal 57: 301
• 19 Vane JR. 1971; Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology 231: 232
• 20 Weiss HJ, Aledort LM, Kochwa S. 1968; The effect of salicylates on the hemostatic properties of platelets in man. Journal of Clinical Investigation 47: 2169
• 21 Weksler BB, Marcus AJ, Jaffe EA. 1977; Synthesis of PGI₂ (prostacyclin) by cultured human and bovine endothelial cells. Proceedings of the National Academy of Sciences, USA 74: 3922
• 22 Zucker MB, Peterson J. 1970; Effect of acetylsalicylic acid, other nonsteroidal antiinflammatory agents and dipyridamole on human blood platelets. Journal of Laboratory and Clinical Medicine 76: 66